Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Broad-Spectrum Vaccine To Prevent Cervical Cancer Induces Strong Responses In Animals
Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published in the May 26 online issue of the Journal of the National Cancer Institute.
generic viagra online
The European Association For The Study Of The Liver Renews Publishing Partnership With Elsevier
Elsevier, the leading publisher of scientific, technical and medical information, is pleased to announce its renewed publishing partnership with The European Association for the Study of the Liver (EASL), the leading European association in the field of liver research. The agreement calls for Elsevier to publish the society"s flagship journal, the Journal of Hepatology, for the next five years.
News of the day
G8 Leaders Launch $20B Initiative To Help Farmers In Developing Countries
The Washington Post reports: "Leaders of the world"s major economies pledged Friday to raise $20 billion over the next three years for food and agricultural aid to the world"s most impoverished countries." According to Obama administration officials, "the U.S. will contribute at least $3.5 billion over the next three years to the worldwide effort," which in addition to the funding, "hopes to better coordinate global food aid efforts and work through initiatives already in place in poor countries around the world, rather than creating new plans," the Washington Post reports (Fletcher, 7/10).
Nutrition

PharmaCom BioVet, Inc. Begins To Review The Process To Potentially Receive Minor Use/Minor Species Drug Approval From FDA

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that the Company has begun the process to potentially apply and endeavor to receive a Minor Use/Minor Species (MUMS) drug approval from the Federal Drug Administration (FDA). Meeting the MUMS requirement is part of the New Drug Approval Process if the Company decides to potentially run clinical trials on a histone deacetylase inhibitor for canines with hemangiosarcoma, which the Corporation is considering the development of. The histone deacetylase inhibitor would be directed for dogs suffering from an acute type of cancer, canine hemangiosarcoma. The Minor Use and Minor Species Animal Health Act became law in 2004. Minor uses are based on there being a small number of animals eligible for treatment with the product in question for the specific intended use. Small numbers have been determined for each of the 7 major species (cows, horses, pigs, chickens, turkeys, dogs, and cats). These have been published in a proposed rule (http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-5385.pdf). To determine if a use is minor, the standard is that the intended use is for a "small number of animals." There is a different "small number" for each of the 7 major species and it reflects the number of animals affected by the disease over a one-year period. "We are continuing to review the FDA filing requirements in order to determine if we may meet the requirements stated by the MUMS Act. By doing so, we potentially progress closer to being able to begin the testing of a novel cancer treatment for canines with Hemangiosarcoma," stated Gary S. Berthold, President of PharmaCom BioVet, Inc. PharmaCom BioVet, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009